HIV infection in women in the United States: Status at the millennium

JAMA

Volumn 285, Issue 9, 2001, Pages 1186-1192

  Hader, Shannon L ^a,b   Smith, Dawn K ^a   Moore, Janet S ^a   Holmberg, Scott D ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DEPRESSION; DISEASE COURSE; DISEASE TRANSMISSION; FEMALE; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; PRIORITY JOURNAL; REVIEW; SEXUAL BEHAVIOR; SURVIVAL TIME; UNITED STATES;

EID: 0035819904     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.285.9.1186     Document Type: Review

References (91)

1. Follow-up on Kaposi's sarcoma and Pneumocystis pneumonia Prevention
2. AIDS in women - United States
3. HIV disease and AIDS in women: Current knowledge and a research agenda
4. Human immunodeficiency virus infection in women
5. Design and baseline characteristics of the Human Immunodeficiency Virus Epidemiology Research (HER) Study: A prospective cohort study of human immunodeficiency virus infection in US women
6. The women's Interagency HIV Study
7. Mortality L285 slide series (through 1998)
8. Interruption of materno-fetal transmission
9. Perinatal prevention guidelines
10. Epidemiology of AIDS in women in the United States 1981 through 1986
11. Is there really a heterosexual AIDS epidemic in the United States? Findings of a multisite validation study, 1992-1995
12. Acquired immunodeficiency syndrome in Alabama: Special concerns for black women
13. Trends in heterosexually acquired AIDS in the United States, 1988-1995
14. Epidemiology of human immunodeficiency virus infection in adolescents, United States
15. Survival with the acquired immunodeficiency syndrome: Experience with 5833 cases in New York City
16. HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and followed up to nine years from seroconversion
17. Survival and disease progression according to gender of patients with HIV infection
18. Does pregnancy influence the course of HIV infection? evidence from two large Swiss cohort studies
19. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS
20. Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men
21. Do gender differences in CD4 cell counts matter?
22. Sex differences in HIV-1 viral load and progression to AIDS
23. Comparison of clinical manifestations of HIV infection among women by risk group, CD4+ cell count, and HIV-1 plasma viral load
24. Sex differences in HIV-1 viral load and progression to AIDS
25. Report of NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
26. Sex differences in longitudinal human immunodeficiency virus type 1 RNA levels among seroconverters
27. Impact of the ovulatory cycle on virologic and immunologic markers in HIV-infected women
28. The spectrum of HIV-1-related disease among out-patients in New York City
29. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy
30. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
31. Comparison of clinical manifestations of HIV infection between male and female injecting drug users
32. Risk for cervical disease in HIV-infected women - New York City
33. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
34. Incidence of cervical squamous intraepithehal lesions in HIV-infected women
35. Incidence and progression of cervical squamous lesions among women with HIV: Insights from the first 13,038 Pap smears of the women's Interagency HIV Study
36. Prevalence and predictors for squamous cell abnormalities in Papanicolaou smears from women infected with HIV-1
37. Human papilloma virus (HPV)-associated vaginal and cervical cytologic abnormalities among women with or at risk for human immunodeficiency virus infection
38. Human papillomavirus infection in women infected with the human immunodeficiency virus
39. Increased prevalence of vulvovaginal condyloma and vulvar intraepithelial neoplasia in women infected with the human immunodeficiency virus
40. Incidence of invasive cervical cancer in HIV seropositive women in New York City
41. Incidence of HPV-associated vulvovaginal lesions in HIV-infected and uninfected women
42. Effect of highly active antiretroviral therapy (HAART) on cervical cytologic changes associated with oncogenic HPV among HIV+ women
43. Prevalence of lower genital tract infections among human immunodeficiency virus (HIV)-seropositive and high-risk HIV-seronegative women
44. Lower genital tract infections among HIV-infected and high-risk uninfected women: Findings of the Women's Interagency HIV Study (WIHS)
45. Influence of human immunodeficiency virus infection on pelvic inflammatory disease
46. Characteristics of menstruation in women infected with human immunodeficiency virus
47. Effect of HIV on menstrual cycle length
48. Update: Trends in AIDS incidence - United States, 1996
49. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
50. Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients
51. Assessment of nutritional status
52. Gender differences in adverse events on ritonavir: An analysis from the Abbott 247 study
53. Clinical factors related to the seventy of fat redistribution in the HIV Outpatient Study (HOPS)
54. Prevalence and risk factors for hyperglycemia, dyslipidemia, and coronary disease among HIV-infected patients on initial protease inhibitor therapy
55. Lactic acidosis in patients receiving nucleoside reverse transcriptase inhibitors
56. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART)
57. Changes in body shape during PI therapy in HIV+ women
58. Nucleoside reverse transcriptase inhibitors associated fat redistribution in HIV-infected women undergoing combined antiretroviral therapy
59. Adherence to antiretroviral therapy among women in the HIV Epidemiology Research Study (HERS) and Women's Interagency HIV Study (WIHS)
60. Who receives highly active antiretroviral therapy (HAART)? Data from a nationally representative sample
61. Adherence in the age of highly active antiretroviral therapy (HAART): Racial and gender differences
62. Predictors of nonadherence to HIV combination therapies
63. Factors associated with adherence to antiretroviral medication by HIV-infected women
64. Variations in the care of HIV-infected adults in the United States
65. Gender differences in quality of life among HIV+ men and women
66. The care of HIV-infected adults in the United States
67. Utilization of health services by HIV+ and HIV- drug injecting prisoners
68. Health care delivery, zidovudine use, and survival of women
69. Health services use by urban women with or at risk for HIV-1 infection: The HIV Epidemiology Research Study (HERS)
70. Access to and utilization of primary care services among HIV- infected women
71. The impact of competing subsistence needs and barriers on access to medical care for persons with human immunodeficiency virus receiving care in the United States
72. Meeting the service needs of HIV-infected persons: Is the Ryan White CARE Act succeeding?
73. Depressive symptoms and CD4 lymphocyte decline among HIV-infected men
74. Affective disorders
75. Severe adverse life events and depressive symptoms among women with, or at risk for, HIV infection in four cities in the United States of America
76. Sex trading and psychological distress among women recruited from the streets of Harlem
77. Psychopathology in male and female HIV-positive and negative injecting drug users: Longitudinal course over 3 years
78. Violence among women with or at risk for HIV infection
79. Domestic violence and childhood sex abuse in HIV-infected women and women at-risk for HIV
80. HIV infection in families of HIV positive and negative at-risk women
81. Women and crack-cocaine use: A study of social networks and HIV risks in an Alabama jail sample
82. Self-reported legal needs of women with or at risk for HIV infection
83. Sexual, contraceptive, and drug use behaviors of women with HIV and those at high risk for infection: Results from the women's Interagency HIV Study
84. Longitudinal study of condom use patterns among women with or at risk for HIV
85. Sexual practices in a cohort of US women with and without human immunodeficiency virus: HIV Epidemiology Research Study
86. Reduced fertility and duration of HIV-1 infection in American women